The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How can more patients access novel agents sooner?
Charles Craddock
December 9, 2019
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, Know AML were pleased to speak to Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK. We asked Charles Craddock: How can we work to accelerate clinical trials so that more patients can access novel agents sooner? Charles Craddock discusses scientific advances such as genomic stratification to guide treatment pathways and the emergence of novel agents in the field of acute myeloid leukemia. He talks about enhancing and reforming clinical trials so that more patients have access to drugs as soon as possible.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
